Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.

Trial Details

NCT ID
NCT06289751
Phase
PHASE2
Sponsor
Tongji Hospital
Status
RECRUITING
Cancer Type
Adenocarcinoma Cervical Cancer
Interventions
  • Cadonilimab
  • Paclitaxel-albumin
  • Cisplatin
  • Extrafascial hysterectomy
  • Radical hysterectomy
  • Cone biopsy
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Clinical diagnosis of untreated stage IB cervical cancer with IB2 (FIGO, 2018 criteria; staging determined by two physicians of associate seniority…
  • At least one measurable lesion at baseline according to RECIST 1.1 criteria, with lesion size based primarily on magnetic resonance imaging;
  • Pathologically confirmed diagnosis of cervical cancer, including cervical squamous cell carcinoma (any grade), usual type adenocarcinoma (G1 or G2 …
  • Positive PD-L1 expression, Combined Positive Score (CPS) ≥1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Cervical Cancer Trials on Trialify →